Guillain-Barre Syndrome (GBS)FOCUS on GBSNCT04829526
Firm Observational Clinical Unicenter Study on Guillain Barré Syndrome
An observational study of Guillain-Barre Syndrome (GBS), run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
The aim of this retrospective observational single-center cohort study is to gain a deeper understanding regarding the frequency, the clinical and electrophysiologic characteristics (e.g., the diagnostic work up), complications, treatment regimes, and their associations with specific courses of disease and outcomes in… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Guillain-Barre Syndrome (GBS)
- What is being tested?
- data collection
- How many people
- 100 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Mar 2021to Jul 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients with the suspected and with the final proven diagnosis of GBS in the years 2005-2021
Who may be able to join
- suspected diagnosis of GBS, who have been treated at the University Hospital of Basel from 01.01.2005-28.02.2021
Who cannot join
- Patients with documented refusal of the general consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Lisa Hert, Dr. med. contact
Switzerland1 site, 1 recruiting
- Recruiting
Clinic for Intensive Care Medicine; University Hospital Basel
Basel, 4031
Raoul Sutter, Prof. Dr. med., raoul.sutter@usb.ch
Lisa Hert, Dr. med., lisa.hert@usb.ch
About this study
Official title: Firm Observational Clinical Unicenter Study on Guillain Barré Syndrome (FOCUS on GBS)
The aim of this retrospective observational single-center cohort study is to gain a deeper understanding regarding the frequency, the clinical and electrophysiologic characteristics (e.g., the diagnostic work up), complications, treatment regimes, and their associations with specific courses of disease and outcomes in adult patients with the suspected or proven diagnosis of GBS.
Read the detailed description
Guillain Barré Syndrome (GBS) is a rare and life-threatening neurological emergency. The aim of this retrospective study including adult GBS patients from the last 15 years treated at the University Hospital of Basel is to assess data regarding diagnostic workup, treatment, clinical course including complications and outcomes.
- Conditions
- Guillain-Barre Syndrome (GBS)
- Being tested
- data collection
- Medical subject headings
- Guillain-Barre Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
data collectionOther
Retrospective extraction of demographic, clinical, laboratory, and electrophysiological data from the digital medical records
What is being measured
The primary outcome is the main question the study is designed to answer.
frequency of GBS
frequency of GBS of all consecutive adult patients with the suspected initial diagnosis of GBS (admitted to the University Hospital Basel)
Measured: one time retrospective assessment at baseline
clinical characteristics of GBS
clinical characteristics of GBS of all consecutive adult patients with the suspected initial diagnosis of GBS (admitted to the University Hospital Basel)
Measured: one time retrospective assessment at baseline
electrophysiologic characteristics of GBS
electrophysiologic characteristics of GBS of all consecutive adult patients with the suspected initial diagnosis of GBS (admitted to the University Hospital Basel)
Measured: one time retrospective assessment at baseline
complications of GBS
complications of GBS of all consecutive adult patients with the suspected initial diagnosis of GBS (admitted to the University Hospital Basel)
Measured: one time retrospective assessment at baseline
treatment regimes of GBS
treatment regimes of GBS of all consecutive adult patients with the suspected initial diagnosis of GBS (admitted to the University Hospital Basel)
Measured: one time retrospective assessment at baseline
outcomes of GBS
treatment regimes of GBS of all consecutive adult patients with the suspected initial diagnosis of GBS (admitted to the University Hospital Basel)
Measured: one time retrospective assessment at baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2021
- Study start1 Mar 2021
- Primary completionJul 2026 (estimated)
- Study completionJul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Guillain-Barre Syndrome (GBS)Studies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Raoul Sutter, Prof. Dr. med., Principal investigator, Clinic for Intensive Care Medicine, University Hospital Basel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04829526
- Sponsor's protocol ID
- 2021-00402; ko21Sutter
- Acronym
- FOCUS on GBS
- Status last verified
- Jun 2026
- First submitted
- 29 Mar 2021
- Last updated
- 17 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Firm Observational Clinical Unicenter Study on Guillain Barré Syndrome (FOCUS on GBS)
- ClinicalTrials.gov ID
- NCT04829526
- Acronym / sponsor ID
- FOCUS on GBS / 2021-00402; ko21Sutter
- Conditions
- Guillain-Barre Syndrome (GBS)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- 1 Mar 2021 (actual)
- Primary completion
- Jul 2026 (estimated)
- Study completion
- Jul 2026 (estimated)
- First posted
- 2 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this retrospective observational single-center cohort study is to gain a deeper understanding regarding the frequency, the clinical and electrophysiologic characteristics (e.g., the diagnostic work up), complications, treatment regimes, and their associations with specific courses of disease and outcomes in adult patients with the suspected or proven diagnosis of GBS.
Detailed description
Guillain Barré Syndrome (GBS) is a rare and life-threatening neurological emergency. The aim of this retrospective study including adult GBS patients from the last 15 years treated at the University Hospital of Basel is to assess data regarding diagnostic workup, treatment, clinical course including complications and outcomes.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients with the suspected and with the final proven diagnosis of GBS in the years 2005-2021
Key inclusion criteria (1 listed)
- suspected diagnosis of GBS, who have been treated at the University Hospital of Basel from 01.01.2005-28.02.2021
Key exclusion criteria (1 listed)
- Patients with documented refusal of the general consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| data collectionRetrospective extraction of demographic, clinical, laboratory, and electrophysiological data from the digital medical records | Other | – |
Primary outcome
frequency of GBS
Time frame: one time retrospective assessment at baseline
frequency of GBS of all consecutive adult patients with the suspected initial diagnosis of GBS (admitted to the University Hospital Basel)
clinical characteristics of GBS
Time frame: one time retrospective assessment at baseline
clinical characteristics of GBS of all consecutive adult patients with the suspected initial diagnosis of GBS (admitted to the University Hospital Basel)
electrophysiologic characteristics of GBS
Time frame: one time retrospective assessment at baseline
electrophysiologic characteristics of GBS of all consecutive adult patients with the suspected initial diagnosis of GBS (admitted to the University Hospital Basel)
complications of GBS
Time frame: one time retrospective assessment at baseline
complications of GBS of all consecutive adult patients with the suspected initial diagnosis of GBS (admitted to the University Hospital Basel)
treatment regimes of GBS
Time frame: one time retrospective assessment at baseline
treatment regimes of GBS of all consecutive adult patients with the suspected initial diagnosis of GBS (admitted to the University Hospital Basel)
outcomes of GBS
Time frame: one time retrospective assessment at baseline
treatment regimes of GBS of all consecutive adult patients with the suspected initial diagnosis of GBS (admitted to the University Hospital Basel)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jun 2026.
Related trials for Guillain-Barre Syndrome (GBS)
Not yet recruitingPhase 2
A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome
Guillain-Barré Syndrome (GBS)
RecruitingPhase 3
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Guillain-Barre Syndrome
Recruiting
Noninvasive Support for Acute Respiratory Failure in Guillain-Barré Syndrome
Guillain-Barre Syndrome
RecruitingObservational study
Cohort Study on Neuroimmune Diseases in the Reproductive Age
Neuromyelitis Optica Spectrum Disorders (NMOSD), Multiple Sclerosis
RecruitingObservational study
Living With Guillain-Barré Syndrome as Children.
Guillain Barré Syndrome, Guillain-Barré Syndrome (GBS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lisa Hert, Dr. med. contact
Raoul Sutter, Prof. Dr. med. principal investigator
Clinic for Intensive Care Medicine, University Hospital Basel
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Guillain-Barre Syndrome (GBS), run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Raoul Sutter, Prof. Dr. med. (+41 61 32 87 928, raoul.sutter@usb.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
frequency of GBS (time frame: one time retrospective assessment at baseline). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jun 2026.